StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
MOLNMOLECULAR PARTNERS AG
stockpulse.co.kr
Nasdaq
$3.67▼ 2.65%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $137.7MShares out 37.5M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

1
  • 8.25Pre-market26.08.25 19:03
    6-KKey event#●●●#●●●#●●●

    MOLECULAR PARTNERS AG

    Molecular Partners reported a net loss of CHF 26.7 million for the first half of 2026, with cash and cash equivalents of CHF 67.9 million as of June 30, 2026, sufficient to fund operations into late 2027. The company's lead radiopharmaceutical candidate, MP0712, has successfully advanced to the second dose level in its Phase 1/2a clinical trial following positive safety data.…more

    $3.67-2.65%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare

News

GlobeNewswire
  • 3d agoOvernight26.10.22 14:37
    #●●●#●●●

    Molecular Partners Selects MP0730 for Kidney Cancer Radiotherapy

    Molecular Partners has selected MP0730 as its lead candidate for CD70-targeted alpha therapy in kidney cancer, marking its third radiotherapeutics program. The company expects to initiate first-in-human trials by 2027, though the project remains in the early development stage.…more

    $3.67-2.65%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.25Regular26.08.26 04:02

    ●●●●●●●● ●●●●● ●●●●●●

    Molecular Partners announced that its DLL3-targeting radiotherapy candidate, MP0712, has advanced to the next dose level in its Phase 1/2a clinical trial. While the company has secured funding through 2027, it continues to report net losses for the first half of 2026.…more

    $3.67-2.65%vs prev close
    Read sourceShareGlobeNewswire
  • 8.25Pre-market26.08.25 19:15

    ●●●●●●●● ●●●●● ●●●●●●

    Molecular Partners reported a quarterly loss of $0.89 per share, significantly missing the analyst consensus estimate of $0.45. The results represent a 31.34% increase in losses compared to the same period last year.…more

    $3.67-2.65%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →